secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001104659-25-100801
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience raises $50M in PIPE; accelerates ALTO-207 in TRD after FDA meeting
--------------------------------------------------------------------------------

- Gross proceeds of ~$50M from PIPE led by Perceptive Advisors; priced at $5.914/share plus pre-funded warrants at $5.9139.
- Proceeds to accelerate ALTO-207 development in treatment-resistant depression; Phase 2b potentially pivotal by mid-2026, Phase 3 by early 2027.
- Successful FDA meeting for ALTO-207 guides accelerated path; blinded PK data from ALTO-100 and ALTO-101 showed 96% and 100% compliance.
- Terminated $75M Sales Agreement with Leerink Partners; no shares sold under it.
- Cash runway extended into 2028 including additional ALTO-207 activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/0001104659-25-100801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer